<DOC>
	<DOCNO>NCT01462578</DOCNO>
	<brief_summary>Assessment efficacy azacitidine prevent relapse</brief_summary>
	<brief_title>Treatment Patients With Myelodysplastic Syndrome Acute Myelocytic Leukemia With Impending Hematological Relapse With Azacitidine ( Vidaza )</brief_title>
	<detailed_description>Analysis effectiveness azacitidine 6 month start therapy prevent hematological relapse MDS AML patient significant residual increase minimal residual disease ( MRD ) define : - decrease CD34 donor chimerism ( &lt; 80 % ) allogeneic relate unrelated HSCT CD34+ CD117+ MDS AML - increase AML-specific molecular marker quantitative PCR ( 6,9 ) , NPM1+ AML &gt; 1 % ( ratio reference gene ) conventional chemotherapy allogeneic HSCT - persistence ( ) MRD level &gt; 1 % conventional chemotherapy allogeneic HSCT - tolerance azacitidine - quality response MRD ( major vs. minor ) relapse-free survival overall survival 12 , 24 30 month start treatment azacitidine - modulation CD34+ , NK- T-cells MDS AML patient azacitidine</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Screening : sign informed consent Age â‰¥18 year patient MDS AML conventional chemotherapy allogeneic HSCT positive molecular marker ( 6,9 ) , NPM1 po . CD34+ CD117+ case allogeneic HSCT Treatment : MDS AML without haematological relapse ( blast &lt; 5 % bone marrow ) , decrease CD34 donor chimerism ( &lt; 80 % ) allogeneic relate unrelated HSCT CD34+ CD117+ MDS AML increase AMLspecific molecular marker quantitative PCR ( 6,9 ) , NPM1+ AML &gt; 1 % conventional chemotherapy allogeneic HSCT persistence ( ) MRD level &gt; 1 % ( relative reference gene ) conventional chemotherapy allogeneic HSCT leukocytes &gt; 3 Gpt/l platelet &gt; 75 Gpt/l ( transfusion independent ) Known history hypersensitivity drug use constituent drug similar chemical structure , Participation patient another clinical trial within last 4 week inclusion addiction disorder allow concerned person , assess nature scope possible consequence clinical investigation pregnant breast feed woman woman childbearing potential , except woman meet follow criterion : postmenopausal ( 12 month natural amenorrhea 6 month amenorrhea serum FSH &gt; 40 U/ml ) postoperative ( 6 week hysterectomy without bilateral ovariectomy ) regular proper use contraceptive method error rate &lt; 1 % per year ( e.g. , implant , depot injection , oral contraceptive , intrauterine device , IUD ) study treatment 1 year completion therapy sexual abstinence study treatment 1 year completion therapy Vasectomy partner Men use one follow type effective contraception study treatment 1 year completion therapy : sexual abstinence State postvasectomy Condom Evidence participate person expect comply protocol ( lack cooperation ) Uncontrolled active infection Severe hepatic impairment ( AST ALT may exceed three time normal ) liver cirrhosis malignant liver tumor Dialysis dependent renal dysfunction Known severe congestive heart failure , incidence clinically unstable cardiac pulmonary disease These criterion screen phase know allergic reaction azacitidine intolerance apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Neoplasms benign , malignant unspecified</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>